EA200401369A1 - Замедленно высвобождающие лекарственные композиции гвайфенезина - Google Patents

Замедленно высвобождающие лекарственные композиции гвайфенезина

Info

Publication number
EA200401369A1
EA200401369A1 EA200401369A EA200401369A EA200401369A1 EA 200401369 A1 EA200401369 A1 EA 200401369A1 EA 200401369 A EA200401369 A EA 200401369A EA 200401369 A EA200401369 A EA 200401369A EA 200401369 A1 EA200401369 A1 EA 200401369A1
Authority
EA
Eurasian Patent Office
Prior art keywords
guaifenesin
composition
modified release
releasing
dosing
Prior art date
Application number
EA200401369A
Other languages
English (en)
Other versions
EA007156B1 (ru
Inventor
Роберт Д. Дэвис
Рольф В. Блюм
Доналд Джеффри Кейсер
Original Assignee
Адамс Лэборетриз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/121,706 external-priority patent/US6955821B2/en
Priority claimed from US10/406,574 external-priority patent/US7985420B2/en
Priority claimed from US10/406,557 external-priority patent/US7838032B2/en
Application filed by Адамс Лэборетриз, Инк. filed Critical Адамс Лэборетриз, Инк.
Publication of EA200401369A1 publication Critical patent/EA200401369A1/ru
Publication of EA007156B1 publication Critical patent/EA007156B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Изобретение касается новой фармацевтической композиции с модифицированным высвобождением гвайфенезина и, произвольно, второго лекарственного препарата, который предпочтительно отобран из декстрометорфана и псевдоэфедрина. Композиция может включать гидрофильный полимер, предпочтительно гидроксипропилметилцеллюлозу, и нерастворимый в воде полимер, предпочтительно акриловую смолу, в соотношении в пределах приблизительно 1:1 (один к одному) - 9:1 (девять к одному), более предпочтительно в пределах приблизительно 3:2 (три к двум) - 6:1 (шесть к одному) и наиболее предпочтительно в пределах приблизительно 2:1 (два к одному) - 4:1 (четыре к одному), по весу. Эта композиция способна обеспечивать терапевтически эффективное бионакопление гвайфенезина в организме человека по меньшей мере в течение двенадцати часов после дозировки. Изобретение также касается модифицировано высвобождающего продукта, который состоит из двух частей: одна часть включает немедленно высвобождающую композицию гвайфенезина, а другая часть - замедленно высвобождающую композицию гвайфенезина, где одна или обе части дополнительно включают декстрометорфан. Модифицировано высвобождающий продукт обеспечивает максимальную плазменную концентрацию гвайфенезина, которая эквивалентна концентрации, созданной немедленно высвобождающей таблеткой гвайфенезина, и способна к обеспечению терапевтически эффективного бионакопления гвайфенезина в организме человека в течение по крайней мере двенадцати часов после дозировки.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200401369A 2002-04-15 2003-04-15 Замедленно высвобождающие лекарственные композиции гвайфенезина EA007156B1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10/121,706 US6955821B2 (en) 2000-04-28 2002-04-15 Sustained release formulations of guaifenesin and additional drug ingredients
US10/406,574 US7985420B2 (en) 2000-04-28 2003-04-04 Sustained release of guaifenesin combination drugs
US10/406,557 US7838032B2 (en) 2000-04-28 2003-04-04 Sustained release of guaifenesin
PCT/US2003/011500 WO2003088952A1 (en) 2002-04-15 2003-04-15 Sustained release of guaifenesin combination drugs

Publications (2)

Publication Number Publication Date
EA200401369A1 true EA200401369A1 (ru) 2005-06-30
EA007156B1 EA007156B1 (ru) 2006-08-25

Family

ID=29255202

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200401369A EA007156B1 (ru) 2002-04-15 2003-04-15 Замедленно высвобождающие лекарственные композиции гвайфенезина

Country Status (10)

Country Link
EP (1) EP1503739A4 (ru)
JP (1) JP5466346B2 (ru)
CN (1) CN1655766B (ru)
AU (1) AU2003237807B2 (ru)
CA (1) CA2481739C (ru)
EA (1) EA007156B1 (ru)
IL (1) IL164438A0 (ru)
MX (1) MXPA04010225A (ru)
WO (1) WO2003088952A1 (ru)
ZA (1) ZA200409171B (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2580652C2 (ru) * 2009-02-04 2016-04-10 Астеллас Фарма Инк. Фармацевтическая композиция для орального введения

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR040682A1 (es) 2002-07-25 2005-04-13 Pharmacia Corp Forma de dosificacion una vez al dia de pramipexol
WO2005030132A2 (en) * 2003-09-24 2005-04-07 Combinatorx, Incorporated Therapeutic regimens for administering drug combinations
CA2476101A1 (en) * 2004-08-12 2006-02-12 Bernard Charles Sherman Extended-release capsules comprising venlafaxine hydrochloride
CN101849921A (zh) * 2004-08-13 2010-10-06 贝林格尔·英格海姆国际有限公司 包含普拉克索或其可药用盐的延长释放片剂
PT3184526T (pt) 2005-12-13 2018-12-19 Incyte Holdings Corp Derivados de pirrolo[2,3-d]pirimidina como inibidores da cinase janus
CN1994285B (zh) * 2006-01-04 2011-03-16 上海医药工业研究院 愈创木酚甘油醚缓释微丸及其制备方法
US20080176955A1 (en) * 2007-01-16 2008-07-24 Victory Pharma, Inc. Combined administration of benzonatate and guaifenesin
CN101658507B (zh) * 2008-08-26 2011-12-07 北京科信必成医药科技发展有限公司 一种愈创木酚甘油醚和伪麻黄碱的复方缓释制剂
TWI766281B (zh) 2010-03-10 2022-06-01 美商英塞特控股公司 作為jak1抑制劑之哌啶-4-基三亞甲亞胺衍生物
US9339478B2 (en) 2011-02-04 2016-05-17 Reckitt Benckiser Llc Pharmaceutical formulation
EA201490042A1 (ru) 2011-06-20 2014-10-30 Инсайт Корпорейшн Азетидинил-фенил-, пиридил- или пиразинилкарбоксамидные производные как ингибиторы jak
CN102755304A (zh) * 2012-08-03 2012-10-31 四川百利药业有限责任公司 一种愈美胶囊的制备方法
SG11201503695XA (en) 2012-11-15 2015-06-29 Incyte Corp Sustained-release dosage forms of ruxolitinib
US9655854B2 (en) 2013-08-07 2017-05-23 Incyte Corporation Sustained release dosage forms for a JAK1 inhibitor
CN105982860B (zh) * 2015-02-11 2020-04-14 北京科信必成医药科技发展有限公司 愈创甘油醚无水吞服掩味颗粒
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4552899A (en) * 1984-04-09 1985-11-12 Analgesic Associates Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
US5032406A (en) * 1989-02-21 1991-07-16 Norwich Eaton Pharmaceuticals, Inc. Dual-action tablet
DE69940557D1 (de) * 1998-12-11 2009-04-23 Nostrum Pharmaceuticals Inc Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
CN100391438C (zh) * 1999-09-14 2008-06-04 史密丝克莱恩比彻姆公司 制备水性包被小球粒的方法
US6372525B1 (en) * 1999-12-20 2002-04-16 Taiwan Semiconductor Manufacturing Company Wafer-level antenna effect detection pattern for VLSI
US6372252B1 (en) * 2000-04-28 2002-04-16 Adams Laboratories, Inc. Guaifenesin sustained release formulation and tablets
US20020022058A1 (en) * 2000-07-08 2002-02-21 Lovercheck Dale R. Unit dose of material in system and method

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2580652C2 (ru) * 2009-02-04 2016-04-10 Астеллас Фарма Инк. Фармацевтическая композиция для орального введения

Also Published As

Publication number Publication date
IL164438A0 (en) 2005-12-18
AU2003237807A1 (en) 2003-11-03
EP1503739A1 (en) 2005-02-09
ZA200409171B (en) 2005-07-27
CN1655766A (zh) 2005-08-17
CN1655766B (zh) 2012-05-30
WO2003088952A1 (en) 2003-10-30
JP2005528402A (ja) 2005-09-22
EP1503739A4 (en) 2006-06-21
MXPA04010225A (es) 2005-07-05
JP5466346B2 (ja) 2014-04-09
CA2481739A1 (en) 2003-10-30
EA007156B1 (ru) 2006-08-25
AU2003237807B2 (en) 2008-10-23
CA2481739C (en) 2012-10-02

Similar Documents

Publication Publication Date Title
EA200401369A1 (ru) Замедленно высвобождающие лекарственные композиции гвайфенезина
Bouteille et al. Treatment perspectives for human African trypanosomiasis
Davis et al. Artemisinin‐based combination therapies for uncomplicated malaria
TW200727919A (en) Guaifenesin sustained release formulation and tablets
BR9405798A (pt) Métodos para liberação in vivo de material biológico e composições úteis dos mesmos
US20240041900A1 (en) Glutamine antagonists for the treatment of cognitive deficits and psychiatric disorders
ATE235895T1 (de) Arzneistoff-abgabesystem enthaltend eine festgepackte, feste arzneistoffbasis
CA2309328A1 (en) Cyclic amine derivatives and their use as drugs
AR023972A1 (es) Composiciones de medicamentos a base de compuestos anticolinergicamente activos y beta-mimeticos
AR023939A1 (es) COMPUESTOS DERIVADOS DE PIPERIDINA uTILES COMO ANTAGONISTAS DE CCR5, COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN, EL USO DE LOS MISMOS SOLOS O EN COMBINACIoN CON OTRO AGENTE ANTIVIRAL PARA LA PREPARACIoN DE UN MEDICAMENTO Y UN KIT
De Clercq et al. Efficacy of artesunate and praziquantel in Schistosomahaematobium infected schoolchildren
EA200700049A1 (ru) Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением
WO2007000778A3 (en) Modified release pharmaceutical compositions on the basis of two polymers and processes thereof
HUP0302857A2 (hu) Gyógyszerészeti kiszerelés
IT1245890B (it) Formulazioni farmaceutiche per uso orale gastroresistenti contenenti acidi biliari.
JP2008526953A (ja) 炎症性疾患のプラジカンテルでの治療
TW200503775A (en) Pharmaceutical composition and method for treating
EP1830191A3 (en) Pharmaceutical preparations containing thiazolidinediones for the treatment of endocrine autoimmune diseases
BR0314797A (pt) Derivados da pirimidineamida e o uso dos mesmos
EA200600817A1 (ru) Антагонисты в1 рецептора брадикинина (варианты), фармацевтическая композиция, лекарственное средство, способ лечения заболеваний (варианты)
Meyer et al. Rewarding effects of the optical isomers of 3, 4-methylenedioxy-methylamphetamine (‘Ecstasy’) and 3, 4-methylenedioxy-ethylamphetamine (‘Eve’) measured by conditioned place preference in rats
BR0211198A (pt) Composições farmacêuticas e seu uso
WO2004078147A3 (en) Oxytocin controlled release formulations and methods of using same
HUP0400115A2 (hu) Gyógyászati készítmény fulvesztrant intramuszkuláris beadására
DE60301351D1 (de) Pharmazeutische Desmopressin-Zubereitung als feste Darreichungsform und Methode zu ihrer Herstellung

Legal Events

Date Code Title Description
PC4A Registration of transfer of a eurasian patent by assignment
PD4A Registration of transfer of a eurasian patent in accordance with the succession in title
TC4A Change in name of a patent proprietor in a eurasian patent

Designated state(s): AM AZ BY KZ KG MD TJ TM

PD4A Registration of transfer of a eurasian patent in accordance with the succession in title
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU